{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:59:55Z","timestamp":1790780395766,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>DREAMM-2 (NCT03525678) is an ongoing global, open-label, phase 2 study of single-agent belantamab mafodotin (belamaf; GSK2857916), a B-cell maturation antigen-targeting antibody-drug conjugate, in a frozen-liquid presentation in patients with relapsed\/refractory multiple myeloma (RRMM). Alongside the main study, following identical inclusion\/exclusion criteria, a separate patient cohort was enrolled to receive belamaf in a lyophilised presentation (3.4\u2009mg\/kg, every 3 weeks) until disease progression\/unacceptable toxicity. Primary outcome was independent review committee-assessed overall response rate (ORR). Twenty-five patients were enrolled; 24 received \u22651 dose of belamaf. As of 31 January 2020, ORR was 52% (95% CI: 31.3\u201372.2); 24% of patients achieved very good partial response. Median duration of response was 9.0 months (2.8\u2013not reached [NR]); median progression-free survival was 5.7 months (2.2\u20139.7); median overall survival was not reached (8.7 months\u2013NR). Most common grade 3\/4 adverse events were keratopathy (microcyst-like corneal epithelial changes, a pathological finding seen on eye examination [75%]), thrombocytopenia (21%), anaemia (17%), hypercalcaemia and hypophosphatemia (both 13%), neutropenia and blurred vision (both 8%). Pharmacokinetics supported comparability of frozen-liquid and lyophilised presentations. Single-agent belamaf in a lyophilised presentation (intended for future use) showed a deep and durable clinical response and acceptable safety profile in patients with heavily pre-treated RRMM.<\/jats:p>","DOI":"10.1038\/s41408-020-00369-0","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T13:02:42Z","timestamp":1603458162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Single-agent belantamab mafodotin for relapsed\/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study"],"prefix":"10.1038","volume":"10","author":[{"given":"Paul G.","family":"Richardson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":false,"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hoos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karrie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"January","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Piontek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne C.","family":"Jewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Opalinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-9323","authenticated-orcid":false,"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"369_CR1","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.14694\/EDBK_159516","volume":"36","author":"AK Nooka","year":"2016","unstructured":"Nooka, A. K. & Lonial, S. New targets and new agents in high-risk multiple myeloma. Am. Soc. Clin. Oncol. Educ. Book. 36, e431\u2013e441 (2016).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"369_CR2","doi-asserted-by":"crossref","unstructured":"Gandhi, U. H. et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 33, 2266\u20132275 (2019).","DOI":"10.1038\/s41375-019-0435-7"},{"key":"369_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/ejh.13046","volume":"100","author":"M Pick","year":"2018","unstructured":"Pick, M. et al. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis. Eur. J. Haematol. 100, 494\u2013501 (2018).","journal-title":"Eur. J. Haematol."},{"key":"369_CR4","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.1158\/1078-0432.CCR-16-0184","volume":"22","author":"P Neri","year":"2016","unstructured":"Neri, P., Bahlis, N. J. & Lonial, S. New strategies in multiple myeloma: immunotherapy as a novel approach to treat patients with multiple myeloma. Clin. Cancer Res. 22, 5959\u20135965 (2016).","journal-title":"Clin. Cancer Res."},{"key":"369_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong, K. et al. Multiple myeloma: patient outcomes in real-world practice. Br. J. Haematol. 175, 252\u2013264 (2016).","journal-title":"Br. J. Haematol."},{"key":"369_CR6","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/HS9.0000000000000045","volume":"2","author":"SGR Verelst","year":"2018","unstructured":"Verelst, S. G. R. et al. Long-term outcomes in patients with multiple myeloma: a retrospective analysis of the dutch Population-based HAematological Registry for Observational Studies (PHAROS). HemaSphere. 2, e45 (2018).","journal-title":"HemaSphere."},{"key":"369_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari, A. et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med. 381, 727\u2013738 (2019).","journal-title":"N. Engl. J. Med."},{"key":"369_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/bjh.14145","volume":"174","author":"L Lee","year":"2016","unstructured":"Lee, L. et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br. J. Haematol. 174, 911\u2013922 (2016).","journal-title":"Br. J. Haematol."},{"key":"369_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91\u201398 (2004).","journal-title":"J. Exp. Med."},{"key":"369_CR10","doi-asserted-by":"crossref","unstructured":"Tai, Y.-T. et al. Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 123, 3128\u20133138 (2014).","DOI":"10.1182\/blood-2013-10-535088"},{"key":"369_CR11","doi-asserted-by":"crossref","unstructured":"Montes De Oca, R. et al. The anti-BCMA antibody-drug conjugate GSK2857916 drives immunogenic cell death and immune-mediated anti-tumor responses, and in combination with an OX40 agonist potentiates in vivo activity. in Proc 24th Congress of the European Hematology Association Amsterdam, The Netherlands. 2019: PF558.","DOI":"10.1097\/01.HS9.0000560524.63281.bc"},{"key":"369_CR12","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"YT Tai","year":"2015","unstructured":"Tai, Y. T. & Anderson, K. C. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 7, 1187\u20131199 (2015).","journal-title":"Immunotherapy."},{"key":"369_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486\u2013541 (2018).","journal-title":"Cell Death Differ."},{"key":"369_CR14","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel, S. et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 19, 1641\u20131653 (2018).","journal-title":"Lancet Oncol."},{"key":"369_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0196-6","volume":"9","author":"S Trudel","year":"2019","unstructured":"Trudel, S. et al. Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 9, 37 (2019).","journal-title":"Blood Cancer J."},{"key":"369_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207\u2013221 (2020).","journal-title":"Lancet Oncol."},{"key":"369_CR17","doi-asserted-by":"crossref","unstructured":"Lonial S. et al. Pivotal DREAMM-2 Study: single-agent belantamab mafodotin (GSK2857916) in patients with relapsed\/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and\/or intolerant to anti-CD38 monoclonal antibodies (mAbs). in Proc 56th Annual Meeting of the American Society of Clinical Oncology Chicago, USA. 2020: EP436.","DOI":"10.1200\/JCO.2020.38.15_suppl.8536"},{"key":"369_CR18","unstructured":"European Medicines Agency. ICH Q5E Biotechnological\/biological products subject to changes in their manufacturing process: comparability of biotechnological\/biological products. Reference number: CPMP\/ICH\/5721\/03. 2005. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-5-e-comparability-biotechnological\/biological-products-step-5_en.pdf."},{"key":"369_CR19","doi-asserted-by":"crossref","unstructured":"Donaghy, H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. mAbs. 8, 659\u2013671 (2016).","DOI":"10.1080\/19420862.2016.1156829"},{"key":"369_CR20","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"369_CR21","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. (National Cancer Institute, Rockwell, MD, 2009)."},{"key":"369_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0","volume":"8","author":"PG Richardson","year":"2018","unstructured":"Richardson, P. G. et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 8, 109 (2018).","journal-title":"Blood Cancer J."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00369-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00369-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00369-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:36:02Z","timestamp":1670250962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00369-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["369"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-00369-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]},"assertion":[{"value":"3 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.G.R. has received grant funding and personal fees from Celgene, Takeda, and Oncopeptides, and personal fees from Janssen, Karyopharm and Sanofi. H.C.L. has received grant funding and personal fees from Amgen, Celgene, Janssen, and Takeda; personal fees from GSK and Sanofi, and grant funding from Daiichi Sankyo. A.-O.A. declares no conflict of interest. A.D.C. has received grant funding from GSK, BMS, and Novartis; personal fees from Janssen, Takeda, Oncopeptides, Kite Pharma and Seattle Genetics, and personal fees and other association with GSK and Celgene. P.K. has received grant funding from GSK, Amgen, Sanofi, Takeda, Sorrento and Janssen (to the institution) and served on an advisory board for GSK (for which the institution received an honorarium). P.M.V. has received personal fees from Adaptive Biotechnologies, BMS\/Celgene, Janssen, Novartis, Oncopeptides and TeneoBio. A.H., J. Baron, T.P. and J.O. are employees of and hold stocks and shares in GSK. K.W. and S.R. are employees of GSK. J. Byrne is an employee of GSK and holds stocks\/shares in GSK, Adaptimmune, and Novartis. I.G. and R.C.J. are employees of GSK and hold stocks\/shares in GSK and Novartis. S.L. has received grant funding and personal fees from Celgene and Takeda, and personal fees from Novartis, BMS, GSK, Amgen, Merck and Janssen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"106"}}